Pricing Log in Create free account

Madrigal Pharmaceuticals, Inc. (MDGL) vs Summit Therapeutics PLC (SMMT)

Madrigal Pharmaceuticals, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Summit Therapeutics PLC is the larger, with a market value of $12.3B against $10.6B — 1.2× the size. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against −61.0%. Summit Therapeutics PLC has the higher net margin (0.00% vs −25.3%) and the higher return on invested capital (0.00% vs −787.3%). Across the 17 metrics below, Summit Therapeutics PLC leads on 9 and Madrigal Pharmaceuticals, Inc. on 8.

Valuation

Metric MDGL SMMT Biotechnology median
P/E n/m n/m 8.50
P/S 10.21 16,148.72 9.71
P/B 25.03 18.07 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 9.82 15,310.43 9.21
Earnings yield (2.87%) (7.66%) (33.15%)
Free cash flow yield (1.60%) (4.04%) (25.50%)

Profitability

Metric MDGL SMMT Biotechnology median
Gross margin 91.48% 100.00% 65.16%
Operating margin (25.13%) 0.00% 0.00%
Net margin (25.32%) 0.00% 0.00%
Free cash flow margin (16.07%) 0.00% 0.00%
Return on equity (53.31%) (192.50%) (56.36%)
Return on assets (28.77%) (159.09%) (48.04%)
Return on invested capital (787.33%) 0.00% 0.00%

Growth

Metric MDGL SMMT Biotechnology median
Revenue growth (TTM) 149.04% (61.03%) 6.02%
EPS growth (last fiscal year) 41.32% (364.52%) 30.26%
Revenue growth, 5-year CAGR — (46.49%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDGL SMMT Biotechnology median
Debt to equity 0.65 0.00 0.00
Current ratio 3.20 6.96 4.72
Net debt to EBITDA 2.21 0.65 0.96

Dividend

Metric MDGL SMMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MDGL SMMT Biotechnology median
Market cap 10.62b 12.26b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack